Clarametyx Biosciences will receive $2.6 million to develop CMTX-301, a vaccine designed to prevent bacterial biofilm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback